Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
2024 full-year revenue guidance raised by US$ 2 billion
Highly effective preservation solutions ensuring the safety and protection of personal care products
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Subscribe To Our Newsletter & Stay Updated
